Search

Displaying results 3861 - 3870 of 10000 in total
  1. Drug

    Fosigotifator

    go.drugbank.com/drugs/DB19409
    Investigational

    Fosigotifator is under investigation in clinical trial NCT05757141 (An Open-label Exploratory Study of ABBV-CLS-7262 Subjects With Vanishing White Matter Disease).

    Synonyms: Sodium ({(2S)-1,4-bis[2-(4-chloro-3- fluorophenoxy)acetamido]bicyclo[2.2.2]octan-2- yl}oxy)methyl hydrogen phosphate - 2-amino-2- (hydroxymethyl)propane-1,3-diol (1/1/1)
  2. Drug

    Zimberelimab

    go.drugbank.com/drugs/DB17505
    Investigational

    Synonyms: Immunoglobulin g4(231-proline), anti-(human programmed cell death protein 1) (human monoclonal ab122 .gamma.4-chain), disulfide with human monoclonal ab122 .lambda.-chain, dimer, Anti-pd-1 monoclonal antibody gls-010
  3. Drug

    Phenaglycodol

    go.drugbank.com/drugs/DB19373
    Experimental

    Synonyms: 2,3-butanediol, 2-(4-chlorophenyl)-3-methyl-, (+/-)-2-(p-chlorophenyl)-3-methyl-2,3-butanediol
  4. Drug

    Tocilizumab

    go.drugbank.com/drugs/DB06273
    ApprovedInvestigational

    [L12789] It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. … Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions.

    Categories: Interleukin-6 Receptor Antagonist, Cytochrome P-450 CYP3A InducersProducts: ACTEMRA 80 MG/4 ML IV INFUZYONLUK COZELTI KONSANTRESI İÇEREN FLAKON, 4 ADET, ACTEMRA 80 MG/4 ML IV INFUZYONLUK COZELTI KONSANTRESI İÇEREN FLAKON, 1 ADET
  5. Drug

    AZD2315

    go.drugbank.com/drugs/DB06540
    Experimental

    The drug AZD2315, an immunosuppressant developed by AstraZeneca, was in Phase 1 clinical trials for the treatment of rheumatoid arthritis but was discontinued during this phase

    Synonyms: L-ALANINAMIDE, N-(1-OXO-5-PHENYLPENTYL)-L-ALANYL-L-ARGINYL-L-ALANYL-(.ALPHA.S,3R)-3-AMINO-.ALPHA.-METHYL-2-OXO-1-PYRROLIDINEACETYL-L-ALANYL-L-ARGINYL-N-(4-(2-AMINO-2-OXOETHYL)PHENYL)-, ACETATE (1:2), L-ALANINAMIDE, N-(1-OXO-5-PHENYLPENTYL)-L-ALANYL-L-ARGINYL-L-ALANYL-(.ALPHA.S,3R)-3-AMINO-.ALPHA.-METHYL-2-OXO-1-PYRROLIDINEACETYL-L-ALANYL-L-ARGINYL-N-(4-(2-AMINO-2-OXOETHYL)PHENYL)-, DIACETATE
  6. Drug

    Dexketoprofen

    go.drugbank.com/drugs/DB09214
    ApprovedInvestigationalWithdrawn

    Dexketoprofen is a non-steroidal anti-inflammatory drug. It is available in the various countries in Europe, Asia and Latin America.

    International brands: KETRON DMixtures: DEKSİT 25 MG/4 MG TABLET, DETROİTS 25 MG/4 MG FİLM KAPLI TABLET, 15 TABLET
  7. Drug

    Atilotrelvir

    go.drugbank.com/drugs/DB19439
    Investigational

    Atilotrelvir is under investigation in clinical trial NCT05041907 (Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)).

    Synonyms: (1R,4S,6S)-N-{(1S)-1-ciano-2-[(3S)-2-oxopirrolidin-3-il]etil}-5-[(2S)-3,3-dimetil-2-(2,2,2-trifluoroacetamido)butanoil]-5-azaespiro[biciclo[2.2.1]heptano-2,1'-ciclopropano]-6-carboxamida, Spiro[2-azabicyclo[2.2.1]heptane-5,1′-cyclopropane]-3-carboxamide, N-[(1S)-1-cyano-2-[(3S)-2-oxo-3-pyrrolidinyl]ethyl]-2-[(2S)-3,3-dimethyl-1-oxo-2-[(2,2,2-trifluoroacetyl)amino]butyl]-, (1S,3S,4R)-
  8. Drug

    scAAV9.U7.ACCA

    go.drugbank.com/drugs/DB18582
    Investigational

    scAAV9.U7.ACCA is a non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding

    Synonyms: non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding RNA
  9. Drug

    Baricitinib

    go.drugbank.com/drugs/DB11817
    ApprovedInvestigational

    Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. … [A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe.

    Categories: MATE 2 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: UNAMİTY 4 MG FİLM KAPLI TABLET, 7 ADET, UNAMİTY 4 MG FİLM KAPLI TABLET, 14 ADET
  10. Drug

    Raxtozinameran

    go.drugbank.com/drugs/DB18228
    ApprovedInvestigational

    It works by binding to the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is a transmembrane glycoprotein that plays a vital role in viral pathogenesis, evolutions … [A273680] Raxtozinameran was first approved by the FDA and EMA through emergency use in December 2020.[L52565,L39272]

    Synonyms: RBP-020.2 4 (XBB.1.5 variant), RNA (recombinant 5′-[1,2-[(3′-O-methyl)m7G-(5′→5′)-ppp-Am]]-capped all uridine→N1-methylpseudouridine-substituted severe acute respiratory syndrome coronavirus 2 spike glycoprotein secretory signal peptideProducts: COMIRNATY® VACUNA DE ARNM CONTRA COVID-19